Journals / Trends in pediatrics / 2022 / Cilt: 3 - Sayı: 1

Is Plasma C-Type Natriuretic Peptide Level Suitable for Diagnosing and Typing Skeletal Dysplasia?

Pages
18–23
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further larger studies are necessary to assess the use CNP as a marker for the diagnosis and typing of skeletal dysplasia.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Skeletal dysplasia is a heterogeneous group of diseases that lead to abnormal enchondral ossification and typing of the disease is quite complex.
📊
Key Findings & Data:Methods: Thirty-seven patients aged six months to 18 years [26 (70.3%) girls] were included in this cross-sectional study from among 75 skeletal dysplasia patients.
💡
Conclusion & Impact:Further larger studies are necessary to assess the use CNP as a marker for the diagnosis and typing of skeletal dysplasia.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Skeletal dysplasia is a heterogeneous group of diseases that lead to abnormal enchondral ossification and typing of the disease is quite complex. C-type natriuretic peptide (CNP), one of the members of the natriuretic peptide family, has been implicated in bone development, and CNP levels are high in some types of skeletal dysplasia. The aim of this study was to evaluate the use of CNP as a marker for skeletal dysplasia types and to investigate its role in typing. Methods: Thirty-seven patients aged six months to 18 years [26 (70.3%) girls] were included in this cross-sectional study from among 75 skeletal dysplasia patients. All subjects were physically examined; anthropometric measurements were obtained, and bone surveys were evaluated. ELISA was used to assess CNP plasma levels. Forty-nine healthy children aged six months to 18 years [24 girls (49%)] comprised the control group. Results: The CNP concentration of the patient group (n=37) was 1.31±1.40 ng/mL which was similar to the control group (n=49) at 1.04±1.40 ng/mL (p=0.207). However, the CNP concentration of patients with achondroplasia (n=17) was significantly higher (1.79±1.64 ng/mL) than the control group (p=0.032). Conclusion: Our study contributes evidence concerning CNP values of both healthy children and children with skeletal dysplasia. Compared with healthy children, those with achondroplasia have elevated plasma levels of CNP. Further larger studies are necessary to assess the use CNP as a marker for the diagnosis and typing of skeletal dysplasia.

🔖

Cite This Article

DARCAN, Ş., GÖKŞEN, D., ÖZEN, S., ÖZGÜR, S., ALPER, H., IŞIK, E., ÇETİN, S. K. (2022). Is Plasma C-Type Natriuretic Peptide Level Suitable for Diagnosing and Typing Skeletal Dysplasia?. Trends in pediatrics, Cilt: 3 - Sayı: 1, 18–23. https://ajindex.com/articles/598879

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Vasques GA, Arnhold IJ, Jorge AA. Role of the natriuretic peptide system in normal growth and growth disorders. Horm Res Paediatr. 2014;82:222-9
  2. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev. 2006;27:47-72
  3. Demirtaş S, Karaboğa İ, Karaca T. Natriüretik Peptitler. Int J Basic Clin Med. 2016;2:157-64
  4. Olney RC, Prickett TC, Espiner EA, et al. C-type natriuretic peptide plasma levels are elevated in subjects with achondroplasia, hypochondroplasia, and thanatophoric dysplasia. J Clin Endocrinol Metab. 2015;1002:E355-E9
  5. Mortier GR, Cohn DH, Cormier‐Daire V, et al. Nosology and classification of genetic skeletal disorders: 2019 revision. Am J Med Genet A. 2019;17912:2393-419
  6. Neyzi O, Bundak R, Gökçay G, et al. Reference values for weight, height, head circumference, and body mass index in Turkish children. J Clin Res Pediatr Endocrinol. 2015;74:280-93
  7. Tanner J, Whitehouse R. Standards for sitting height and subischial leg length from birth to maturity: British children 1978. Castlemead, Hertford. 1979
  8. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist: Stanford university press; 1959
  9. Brunner E, Puri ML. Nonparametric methods in factorial designs. Statistical Papers. 2001;42:1-52
  10. Olney RC, Bü kü lmez Hl, Bartels CF, et al. Heterozygous mutations in natriuretic peptide receptor-B (NPR2) are associated with short stature. J Clin Endocrinol Metab. 2006;91:1229-32
  11. Hisado-Oliva A, Ruzafa-Martin A, Sentchordi L, et al. Mutations in C-natriuretic peptide (NPPC): a novel cause of autosomal dominant short stature. Genet Med. 2018;20:91-7
  12. Yasoda A, Nakao K. Translational research of C-type natriuretic peptide (CNP) into skeletal dysplasias. Endocr J. 2010;57:659-66
  13. Foreman PK, van Kessel F, van Hoorn R, van den Bosch J, Shediac R, Landis S. Birth prevalence of achondroplasia: A systematic literature review and meta‐analysis. Am J Med Genet A. 2020;182:2297-316
  14. Ornitz DM, Legeai‐Mallet L. Achondroplasia: Development, pathogenesis, and therapy. Dev Dyn. 2017;246:291-309
  15. Ozasa A, Komatsu Y, Yasoda A, et al. Complementary antagonistic actions between C-type natriuretic peptide and the MAPK pathway through FGFR-3 in ATDC5 cells. Bone. 2005;36:1056-64
  16. Yasoda A, Kitamura H, Fujii T, et al. Systemic administration of C-type natriuretic peptide as a novel therapeutic strat